Alnylam Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $1,249,026 | $773,689 | $594,189 | $593,166 |
Gross Profit | 1,051,795 | 630,736 | 523,148 | 490,349 |
EBITDA | 297,170 | 18,832 | 11,455 | -140,911 |
EBIT | 283,367 | 4,888 | -2,950 | -155,079 |
Net Income | 251,084 | -66,277 | -57,479 | -83,763 |
Net Change In Cash | 1,249,026 | 773,689 | 594,189 | 593,166 |
Free Cash Flow | 312,967 | 139,437 | -127,284 | -103,756 |
Cash | 1,490,249 | 1,113,685 | 1,019,654 | 966,428 |
Basic Shares | 137,348 | 129,676 | 129,676 | 128,590 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $2,248,243 | $1,828,292 | $1,037,418 | $844,287 |
Gross Profit | 1,924,873 | 1,517,886 | 868,601 | 704,143 |
EBITDA | -178,847 | -258,242 | -926,557 | -661,556 |
EBIT | -235,517 | -312,296 | -971,025 | -709,123 |
Net Income | -278,157 | -440,242 | -1,131,156 | -852,824 |
Net Change In Cash | 2,248,243 | 1,828,292 | 1,037,418 | 844,287 |
Cost of Revenue | 53,833 | 332,125 | ||
Free Cash Flow | -42,589 | 41,945 | -613,333 | -718,065 |
Cash | 966,428 | 812,688 | 866,394 | 819,975 |
Basic Shares | 127,651 | 124,906 | 121,689 | 118,451 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | $2.90 |
2025-06-30 | -$0.51 |
2025-03-31 | -$0.01 |
